Urologic Oncology Articles

Crawford Highlights Role of Degarelix in Prostate Cancer
E. David Crawford, MD, shares insight on incorporating ADT, specifically degarelix, into the prostate cancer landscape and why it remains to be a standard go-to approach for patients.
Expert Discusses State of Immunotherapy in Prostate Cancer
Susan F. Slovin, MD, PhD, discusses the current state of immunotherapy in prostate cancer.
Sacituzumab Govitecan Shows Promise in Urothelial Cancer
Scott Tagawa, MD, discusses the latest findings with sacituzumab govitecan in patients with metastatic urothelial cancer.
Evidence Builds for Targeting PD-1/PD-L1 Pathway in Bladder Cancer
As the number of tumor types with approved PD-1/PD-L1 pathway inhibitors continues to expand, bladder cancer has become a robust area of development.
Arlene O. Siefker-Radtke, MD, discusses the exciting advances in the bladder cancer field, why researchers should move past PD-L1 as a biomarker, and what combinations can be expected to move through the pipeline next.
Expert Sees Checkpoint and PARP Inhibitors Building on mCRPC Success
Paul G. Corn, MD, PhD, discusses recent advances in prostate cancer and the potential for immunotherapy and PARP inhibitors in the field.
Researchers Aim to Further Enhance Value of RT in Prostate Cancer
Seungtaek L. Choi, MD, discussed the latest developments with radiation therapy in prostate cancer. 
Gomella Discusses Ongoing Progress With Genetic Testing in Prostate Cancer
Leonard Gomella, MD, discusses the current state and critical next steps for optimizing genetic testing in prostate cancer.
Active Surveillance Remains a Critical Approach for Early Prostate Cancer
Brian F. Chapin, MD, discusses the importance of active surveillance in patients with prostate cancer at a low risk of developing metastases and the benefits of surgery and radiation as active treatment methods for patients with locally advanced disease.
Factors Influencing Patient-Reported Rectal Toxicity Following External Beam Radiation Therapy for Prostate Cancer
Developing and validating a predictive model for patient-reported health-related quality of life remains an elusive target, and one that has great potential to further improve satisfaction with outcome following prostate cancer treatment in a great number of prostate cancer survivors.
Publication Bottom Border
Border Publication